[1]徐君,姚丹珍,夏金盈,等.炎症反应在糖尿病视网膜病变中的作用及相关靶点药物的研究进展[J].眼科新进展,2022,42(8):664-668.[doi:10.13389/j.cnki.rao.2022.0136]
　XU Jun,YAO Danzhen,XIA Jinying,et al.Research progress in the role of inflammatory response in diabetic retinopathy and related targeted drugs[J].Recent Advances in Ophthalmology,2022,42(8):664-668.[doi:10.13389/j.cnki.rao.2022.0136]
点击复制

炎症反应在糖尿病视网膜病变中的作用及相关靶点药物的研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年8期
页码:
664-668
栏目:
文献综述
出版日期:
2022-08-06

文章信息/Info

Title:
Research progress in the role of inflammatory response in diabetic retinopathy and related targeted drugs
作者:
徐君; 姚丹珍; 夏金盈; 李建辉
315000　浙江省宁波市，中国科学院大学宁波华美医院
Author(s):
XU Jun; YAO Danzhen; XIA Jinying; LI Jianhui
Hua Mei Hospital,University of Chinese Academy of Sciences,Ningbo 315000,Zhejiang Province,China
关键词:
糖尿病视网膜病变; 糖尿病黄斑水肿; 炎症反应; 新兴治疗
Keywords:
diabetic retinopathy;  diabetic macular edema;  inflammatory response;  emerging therapies
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2022.0136
文献标志码:
A
摘要:
糖尿病视网膜病变是糖尿病最常见的微血管并发症之一。目前认为炎症反应在糖尿病视网膜病变中起重要作用。非诺贝特、糖皮质激素、抗血管内皮生长因子药物和抗氧化类药物等均可通过抑制炎症发挥治疗作用。炎症调控也是新药研发的一个重要方向。本文对炎症反应在糖尿病视网膜病变中的作用及其相关靶点药物的研究进展进行综述，为治疗糖尿病视网膜病变提供新的思路。
Abstract:
Diabetic retinopathy (DR) is one of the common microvascular complications of diabetes mellitus. It is reported that inflammatory response plays an important role in the development of DR. Drugs like fenofibrate, glucocorticoid, anti-vascular endothelial growth factor drugs and antioxidants have been proven to play positive roles in treating DR by regulating the inflammatory response. It is also a trend to improve current therapies based on the inflammatory response. Therefore, this paper reviews the role of the inflammatory response in DR and related drugs, providing a new direction for the clinical treatment of DR.

参考文献/References:

［1］　RAJALAKSHMI R,PRATHIBA V,ARULMALAR S,USHA M.Review of retinal cameras for global coverage of diabetic retinopathy screening［J］.Eye (Lond),2021,35(1):162-172.
［2］　WONG T Y,SABANAYAGAM C.Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence［J］.Ophthalmologica,2020,243:9-20.
［3］　MESQUIDA M,DRAWNEL F,FAUSER S.The role of inflammation in diabetic eye disease［J］.Semin Immunopathol,2019,41:427-445.
［4］　SERGEYS J,ETIENNE I,HOVE I V,LEFEVERE E,STALMANS I,FEYEN J H M,et al.Longitudinal in vivo characterization of the streptozotocin-induced diabetic mouse model: focus on early inner retinal responses［J］.Invest Ophthalmol Vis Sci,2019,60(2):807-822.
［5］　BINET F,CAGNONE G,CRESPO-GARCIA S,HATA M,NEAULT M,DEJDA A,et al.Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy［J］.Science,2020,369(6506):eaay5356.
［6］　YAO Y,DU J H,LI R,ZHAO L,LUO N,ZHAI J Y,et al.Association between ICAM-1 level and diabetic retinopathy: a review and meta-analysis［J］.Postgrad Med J,2019,95:162-168.
［7］　GUI F,YOU Z P,FU S H,WU H X,ZHANG Y L.Endothelial dysfunction in diabetic retinopathy［J］.Front Endocrinol (Lausanne),2020,11:591.
［8］　WU H L,HWANG D K,SONG X D,TAO Y.Association between aqueous cytokines and diabetic retinopathy stage［J］.J Ophthalmol,2017，2017:9402198.
［9］　BOSS J D,SINGH P K,PANDYA H K,TOSI J,KIM C,TEWARI A,et al.Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy［J］.Invest Ophthalmol Vis Sci,2017,58:5594-5603.
［10］　ZHOU T E,RIVERA J C,BHOSLE V K,LAHAIE I,SHAO Z,TAHIRI H,et al.Choroidal involution is associated with a progressive degeneration of the outer retinal function in a model of retinopathy of prematurity: early role for IL-1β［J］.Am J Pathol,2016,186(12):3100-3116.
［11］　YUN J H.Interleukin-1β induces pericyte apoptosis via the NF-κB pathway in diabetic retinopathy［J］.Biochem Biophys Res Commun,2021,546:46-53.
［12］　SONG Y,TIAN X,WANG X H,FENG H.Vascular protection of salicin on IL-1β-induced endothelial inflammatory response and damages in retinal endothelial cells［J］.Artif Cells Nanomed Biotechnol,2019,47(1):1995-2002.
［13］　LIU X F,YE F,XIONG H B,HU D N,LIMB G A,XIE T,et al.IL-1β induces IL-6 production in retinal Müller cells predominantly through the activation of p38 MAPK/NF-κB signaling pathway［J］.Exp Cell Res,2015,331(1):223-231.
［14］　WANG Y,ZHAI W L,YANG Y W.Association between NDRG2/IL-6/STAT3 signaling pathway and diabetic retinopathy in rats［J］.Eur Rev Med Pharmacol Sci,2020,24(7):3476-3484.
［15］　AN Z J,LI J W,YU J B,WANG X J,GAO H L,ZHANG W,et al.Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages［J］.Cell Cycle,2019,18(21):2928-2938.
［16］　DONG L,BAI J,JIANG X,YANG M M,ZHENG Y,ZHANG H,et al.The gene polymorphisms of IL-8(-251T/A) and IP-10(-1596C/T) are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population［J］.Eye (Lond),2017,31(4):601-607.
［17］　FENG S F,YU H H,YU Y,GENG Y,LI D L,YANG C,et al.Levels of inflammatory cytokines IL-1 β,IL-6,IL-8,IL-17A,and TNF-α in aqueous humour of patients with diabetic retinopathy［J］.J Diabetes Res,2018,2018: 8546423.
［18］　JO D H,YUN J H,CHO C S,KIM J H,KIM J H,CHO C H.Interaction between microglia and retinal pigment epithelial cells determines the integrity of outer blood-retinal barrier in diabetic retinopathy［J］.Glia,2019,67(2):321-331.
［19］　KATELAN S,OREKOVI C＇I,BIC＇AN F,KATELAN H,ANTUNICA A G.Inflammatory and angiogenic biomarkers in diabetic retinopathy［J］.Biochem Med (Zagreb),2020,30(3):030502.
［20］　LI H Y,YUAN Y,FU Y H,WANG Y,GAO X Y.Hypoxia-inducible factor-1α:a promising therapeutic target for vasculopathy in diabetic retinopathy［J］.Pharmacol Res,2020 ,159:104924.
［21］　韩梦雨.新生血管性眼病发病相关细胞因子研究进展［J］.中华实验眼科杂志，2018,36(8):636-642.
HAN M Y.Research progress of pathological relevant cytokines of neovascular eye diseases［J］.Chin J Exp Ophthalmol,2018,36(8):636-642.
［22］　JAIN A,SAXENA S,KHANNA V K,SHUKLA R K,MEYER C H.Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus ［J］.Mol Vis,2013,19:1760-1768.
［23］　RUSNAK S,VRZALOVA J,SOBOTOVA M,HECOVA L,RICAROVA R,TOPOLCAN O.The measurement of intraocular biomarkers in various stages of proliferative diabetic retinopathy using multiplex xMAP technology［J］.J Ophthalmol,2015,2015:424783.
［24］　EYRE J J,WILLIAMS R L,LEVIS H J.A human retinal microvascular endothelial-pericyte co-culture model to study diabetic retinopathy in vitro［J］.Exp Eye Res,2020,201:108293.
［25］　KHALAF N,HELMY H,LABIB H,FAHMY I,HAMID M A E,MOEMEN L.Role of angiopoietins and tie-2 in diabetic retinopathy［J］.Electron Physician,2017,9(8):5031-5035.
［26］　MIAO H,HOU X R,HWANG D K,TAO Y.Vascular endothelial growth factor,basic fibroblast growth factor,and pigment epithelium-derived factor expression in the neovascular iris in retinal diseases［J］.J Ophthalmol,2018,2018:8025951.
［27］　TORRES-COSTA S,VALENTE M C A,FALCO-REIS F,FALCO M.Cytokines and growth factors as predictors of response to medical treatment in diabetic macular edema［J］.J Pharmacol Exp Ther,2020,373(3):445-452.
［28］　NOMA H,YASUDA K,SHIMURA K.Involvement of cytokines in the pathogenesis of diabetic macular edema［J］.Int J Mol Sci,2021,22(7):3427.
［29］　YENIHAYAT F,ZKAN B,KASAP M,KARABAS V L,GZEL N,AKPINAR G,et al.Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid［J］.Int Ophthalmol,2019,39(4):821-828.
［30］　WU J Y,ZHONG Y F,YUE S,YANG K B,ZHANG G S,CHEN L,et al.Aqueous humor mediator and cytokine aberrations in diabetic retinopathy and diabetic macular edema: a systematic review and meta-analysis ［J］.Dis Markers,2019,2019:6928524.
［31］　中华医学会糖尿病分会.中国2型糖尿病防治指南（2020年版）［J］.中华糖尿病杂志，2021,13(4):317-411.
Chinese Diabetes Society.Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)［J］.Chin J Diabetes Mellitus,2021,13(4):317-411.
［32］　JU H B,ZHANG F X,WANG S,SONG J,CUI T,LI L F,et al.Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients［J］.Medicine (Baltimore),2017,96:e7671.
［33］　LIU Q P,ZHANG F J,ZHANG X,CHENG R,MA J X,YI J L,et al.Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation［J］.Mol Cell Biochem,2018,445:105-115.
［34］　CHEN N,JIANG K,YAN G G.Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway［J］.Eur Rev Med Pharmacol Sci,2019,23(19):8630-8636.
［35］　HOLLBORN M,STATHOPOULOS C,STEFFEN A,WIEDEMANN P,KOHEN L,BRINGMANN A.Positive feedback regulation between MMP-9 and VEGF in human RPE cells［J］.Invest Ophthalmol Vis Sci,2007,48:4360-4367.
［36］　HSIAO C C,CHANG Y C,HSIAO Y T,CHEN P H,HSIEH M C,WU W C,et al.Triamcinolone acetonide modulates TGF-β2-induced angiogenic and tissue-remodeling effects in cultured human retinal pigment epithelial cells［J］.Mol Med Rep,2021,24(5):802.
［37］　ALTUNINA N V,LIZOGUB V G,BONDARCHUK O M.Alpha-lipoic acid as a means of influence on systemic inflammation in type 2 diabetes mellitus patients with prior myocardial infarction［J］.J Med Life,2020,13(1):32-36.
［38］　胡辅华,许玉俊,刘丽林,季建,于荣国.α-硫辛酸对糖尿病大鼠视网膜VEGF表达的影响及机制［J］.重庆医学,2015,44(25):3463-3465,3469.
HU F H,XU Y J,LIU L L,JI J,YU R G.The effect of α-lipoic acid on the retinal expression level of VEGF in rats with diabetes mellitus and mechanism ［J］.Chongqing Med,2015,44(25):3463-3465,3469.
［39］　LIN J,BIERHAUS A,BUGERT P,DIETRICH N,FENG Y,HAGEN F V,et al.Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy［J］.Diabetologia,2006,49(5):1089-1096.
［40］　XIA J P,LIU S Q,WANG S.Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress［J］.Life Sci,2021,265:118795.
［41］　WANG T Q,ZHANG C Y ,XIE H,JIANG M M,TIAN H B,LU L X,et al.Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy［J］.Eye Vis (Lond),2021,8(1):13.
［42］　陈翀,刘堃.重视糖尿病黄斑水肿的个体化治疗［J］.中华眼底病杂志,2020,36(2):89-93.
CHEN C,LIU K.Attach importance to individualized treatment of diabetic macular edema［J］.Chin J Ocul Fundus Dis,2020,36(2):89-93.
［43］　BONNIN S,TADAYONI R,ERGINAY A,MASSIN P,DUPAS B.Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema［J］.Invest Ophthalmol Vis Sci,2015,56(2):978-982.
［44］　CHANDRASEKARAN P R,MADANAGOPALAN V G.KSI-301:antibody biopolymer conjugate in retinal disorders［J］.Ther Adv Ophthalmol,2021,13: 25158414211027708.
［45］　SHEN J K,FRYE M,LEE B L,REINARDY J L,MCCLUNG J M,DING K,et al.Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature［J］.J Clin Invest,2014,124(10):4564-4576.
［46］　CAMPOCHIARO P A,KHANANI A,SINGER M,PATEL S,BOYER D,DUGEL P,et al.Enhanced benefit in diabetic macular edema from AKB-9778 tie2 activation combined with vascular endothelial growth factor suppression［J］.Ophthalmology,2016,123(8):1722-1730.
［47］　SAHNI J,PATEL S S,DUGEL P U,KHANANI A M,JHAVERI C D,WYKOFF C C,et al.Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial［J］.Ophthalmology,2019,126(8):1155-1170.
［48］　SILVA R L E,KANAN Y,MIRANDO A C,KIM J,SHMUELI R B,LORENC V E,et al.Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage［J］.Sci Transl Med,2017,9 (373):eaai8030.
［49］　MIRANDO A C,SILVA R L E,CHU Z,CAMPOCHIARO P A,PANDEY N B,POPEL A S.Suppression of ocular vascular inflammation through peptide-mediated activation of angiopoietin-tie2 signaling［J］.Int J Mol Sci,2020,21(14):5142.
［50］　YANG Q H,ZHANG Y,JIANG J,WU M M,HAN Q,BO Q Y,et al.Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina［J］.Int J Ophthalmol,2018,11(6):935-944.
［51］　谷中秀,姜静,黄敏,吴绵绵,郭芳,李慎军,等.不同批次的重组诱饵型受体创新药物RC28-E1与RC28-E2对视网膜新生血管的药效学比较及机制 ［J］.中华实验眼科杂志,2018,36(8):581-589.
GU Z X,JIANG J,HUANG M,WU M M,GUO F,LI S J,et al.Comparison of pharmacodynamics between different batches of recombinant decoy receptor innovative drug RC28-E1 and RC28-E2 in retinal angiogenesis and neovascularization and its mechanism ［J］.Chin J Exp Ophthalmol,2018,36(8):581-589.
［52］　DING K,SHEN J K,HAFIZ Z,HACKETT S F,SILVA R L E,KHAN M,et al.AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression［J］.J Clin Invest,2019,129(11):4901-4911.
［53］　QI F,JIANG X,TONG T,CHANG H,LI R X.MiR-204 inhibits inflammation and cell apoptosis in retinopathy rats with diabetic retinopathy by regulating Bcl-2 and SIRT1 expressions［J］.Eur Rev Med Pharmacol Sci,2020,24(12):6486-6493.
［54］　MA Y B,DU Y H,XU Q,BAO H J,LIU Z L,LI Y C,et al.Inhibiting MiR-34α reduces retinal cell apoptosis and downstream NF-κB pathway in diabetic retinopathy rats through regulating HMGB1 expression［J］.Minerva Med,2020.［Online ahead of print］.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[6]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[7]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[8]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[9]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[10]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[11]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[12]邵毅,周召,葛倩敏.糖尿病视网膜病变及黄斑水肿诊疗规范：英国皇家眼科医师学会指南解读[J].眼科新进展,2021,41(7):601.[doi:10.13389/j.cnki.rao.2021.0125]
　SHAO Yi,ZHOU Zhao,GE Qianmin.Consensus interpretation on the diagnosis and treatment of diabetic retinopathy and diabetic macular edema by the The Royal College of Ophthalmologists[J].Recent Advances in Ophthalmology,2021,41(8):601.[doi:10.13389/j.cnki.rao.2021.0125]
[13]邵毅,李乐妍,魏红.糖尿病黄斑水肿的诊断和治疗进展[J].眼科新进展,2022,42(11):841.[doi:10.13389/j.cnki.rao.2022.0174]
　SHAO Yi,LI Leyan,WEI Hong.Research progress in diagnosis and treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2022,42(8):841.[doi:10.13389/j.cnki.rao.2022.0174]
[14]朱君雅,姚文,倪锡森,等.糖尿病性黄斑水肿的病理生理机制：神经血管单元研究现状[J].眼科新进展,2023,43(1):066.[doi:10.13389/j.cnki.rao.2023.0014]
　ZHU Junya,YAO Wen,NI Xinsen,et al.Pathophysiology of diabetic macular edema: current status of neurovascular unit research[J].Recent Advances in Ophthalmology,2023,43(8):066.[doi:10.13389/j.cnki.rao.2023.0014]
[15]许慕东,朱妍,蔡骐,等.总胆红素水平与糖尿病黄斑水肿发病及严重程度的相关性[J].眼科新进展,2023,43(3):216.[doi:10.13389/j.cnki.rao.2023.0044]
　XU Mudong,ZHU Yan,CAI Qi,et al.Correlation between total bilirubin level and occurrence and severity of diabetic macular edema[J].Recent Advances in Ophthalmology,2023,43(8):216.[doi:10.13389/j.cnki.rao.2023.0044]
[16]邵毅,葛倩敏,陈序.糖尿病黄斑水肿患者行醋酸氟轻松治疗规范：2023年专家共识解读[J].眼科新进展,2023,43(10):757.[doi:10.13389/j.cnki.rao.2023.0152]
　SHAO Yi,GE Qianmin,CHEN Xu.Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema: interpretation of expert consensus 2023[J].Recent Advances in Ophthalmology,2023,43(8):757.[doi:10.13389/j.cnki.rao.2023.0152]

备注/Memo

备注/Memo:
浙江省医药卫生科技计划项目（编号：2021KY1012）
更新日期/Last Update: 2022-08-05